10 May 2023 | 16:00-17:00 CEST
High-efficacy MS therapies may be more effective than lower efficacy options, but they also have more potentially serious side effects. This, combined with patient-to-patient variations in disease course and treatment response, makes decisions around drug selection, initiation, and escalation extremely complex.
In this webinar, leading experts will discuss the multitude of factors associated with high-efficacy treatment outcomes, from severity at diagnosis and initiation timing, to previous treatments and vaccination status.
To provide an understanding of how and when to use high-efficacy therapies in the treatment of people with MS
Value for audience
To receive practice-enhancing guidance on the use of high-efficacy therapies in MS
Moderator: Emma Gray, Assistant Director of Research, MS Society UK
Moderator: Mar Tintore, ECTRIMS President and Head of Care of Neurology, Multiple Sclerosis Centre of Catalonia (CEMCAT)
Speaker: Xavier Montalban, Director of Neurology, Multiple Sclerosis Centre of Catalonia (CEMCAT)
Speaker: Gavin Giovanonni, Chair of Neurology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
Speaker: Dalia Rotstein, Neurologist, Unity Health Toronto, Canada